Physician profile
Michael B Mccabe
NPI 1538425087
$18,172.56
in general payments reported to CMS, 2019-2025
38 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $849 · 2021: $2,237 · 2022: $2,636 · 2023: $2,357 · 2024: $8,745 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,250 · Food and Beverage: $4,268 · Travel and Lodging: $1,736 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,250.00 |
| Food and Beverage | $4,267.75 |
| Travel and Lodging | $1,735.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $6,070.07 | 2024 | Omvoh |
| Abbvie INC. | $3,561.47 | 2019-2025 | |
| Boston Scientific Corporation | $1,722.90 | 2019-2024 | Exalt Model D, Axios |
| Takeda Pharmaceuticals U.S.A., INC. | $1,009.99 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $637.25 | 2019-2025 | Stelara, Simponi, Remicade |
| Gilead Sciences, INC. | $632.53 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $561.92 | 2021-2022 | |
| Celgene Corporation | $482.44 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $369.86 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $308.91 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $256.57 | 2024 | Voquezna |
| Medtronic, INC. | $230.44 | 2023-2024 | Gi Genius, Barrx |
| Lilly USA, LLC | $210.40 | 2023 | |
| Pfizer INC. | $208.85 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $208.75 | 2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $200.08 | 2022 | |
| Conmed Corporation | $186.67 | 2022-2023 | Conmed Biliary, Conmed Generators, Conmed Hemostasis |
| Ethicon US, LLC | $185.48 | 2019-2024 | Linx Reflux Management System, Linx Reflux Management System |
| Intercept Pharmaceuticals, INC. | $169.36 | 2019-2024 | |
| Genzyme Corporation | $158.30 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.63 | 2019 | |
| Merck Sharp & Dohme LLC | $109.22 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $102.63 | 2023-2025 | Dupixent |
| Braintree Laboratories, INC. | $66.64 | 2020-2023 | Sutab |
| Fujifilm Healthcare Americas Corporation | $42.91 | 2023 | Fujifilm |
| Olympus America INC. | $37.77 | 2019-2021 | |
| Cook Medical LLC | $36.66 | 2022 | |
| Ardelyx, INC. | $33.46 | 2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $32.33 | 2022-2023 | |
| Celltrion USA INC. | $31.37 | 2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $29.15 | 2024 | Iqirvo |
| Alexion Pharmaceuticals, INC. | $28.79 | 2019 | |
| Shionogi INC | $27.42 | 2019 | |
| Blueprint Medicines Corporation | $26.86 | 2023 | |
| Laborie Medical Technologies Corp. | $21.04 | 2024 | |
| Organon LLC | $20.36 | 2023 | Renflexis |
| Madrigal Pharmaceuticals | $16.93 | 2024 | Resmetirom |
| Ironwood Pharmaceuticals, INC | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.